Trial Profile

A Phase 2, Double-blind, Randomized, Active-controlled Evaluation of the Safety, Tolerability, Pharmacokinetics and Efficacy of LBP-EC01 in the Treatment of Acute Uncomplicated Urinary Tract Infection Caused by Drug Resistant E. Coli

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Calcium carbonate (Primary) ; Cotrimoxazole (Primary) ; LBP EC01 (Primary) ; LBP EC01 (Primary)
Indications Escherichia coli infections; Urinary tract infections
Focus Pharmacokinetics; Therapeutic Use
Acronyms ELIMINATE; ELIMINATE Trial
Sponsors Locus Biosciences

03 Sep 2025 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
03 Sep 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Jun 2026.
01 Dec 2024 Results defining a dosing regimen of LBP-EC01 for the treatment of uncomplicated UTIs that could advance to the second, randomised, controlled, double-blinded portion of the study, published in The Lancet Infectious Diseases

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com